Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — Shareholder Meeting (August 2018)
33 slides from Aft Pharmaceuticals's shareholder meeting presentation, Aug 3, 2018
Slide 1: AFT Pharmaceuticals Annual Meeting
For personal use only AFT PHARMACEUTICALS Annual Meeting 3 August 2018
Slide 2: Important Notice
For personal use only IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New
Slide 3: Chairman's Introduction
CHAIRMAN’S INTRODUCTION For personal use only Annual Meeting 2 2 August 2018
Slide 4: Order of Meeting
ORDER OF MEETING For personal use only A Chairman’s Address B Chief Executive Officer’s Presentation C Shareholder Questions D Ordinary Resolutions Annual Meeting 3 2 August 2018
Slide 5: Directors' and Executives' Introductions
For personal use only Directors’ and Executives’ Introductions
Slide 6: Chairman's Address
CHAIRMAN’S ADDRESS For personal use only A Overview of Financials B Licensing and registrations C Keys to growth D Corporate governance Annual Meeting 5 2 August 2018
Slide 7: Annual Meeting
For personal use only Annual Meeting 6 2 August 2018
Slide 8: CEO Presentation
For personal use only CEO Presentation
Slide 9: Summary of AFT Business
SUMMARY OF AFT BUSINESS Established Business [1997] and growing AU & NZ Significant further potential growth • - Growing OTC Products For personal use only • - Growing Maxigesic post Codeine switch in AU & NZ post switch Development of Key Innovative Products with Global Potential The most significa
Slide 10: Financial Performance – Revenue Growth
FINANCIAL PERFORMANCE – REVENUE GROWTH Operating revenue, FY2005 – FY2018 90 For personal use only 80 Operating revenue (NZ$m) 70 10 year C AGR: 14% 60 50 40 30 20 10 - FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY2017 Operating revenue by region FY2018 Operating revenue b
Slide 11: Financial Performance – Revenue by Region and Channel
FINANCIAL PERFORMANCE – REVENUE BY REGION AND CHANNEL Operating revenue by region, FY2016 – FY2018 NZ$000's FY2016 % of total FY2017 % of total FY2018 % of total For personal use only Australia 31,224 48.8% 37,063 53.6% 49,193 61.4% YoY growth 18.7% 32.7% New Zealand 31,135 48.6% 29,167 42.1% 27,095
Slide 12: Financial Performance – Summary P&L
FINANCIAL PERFORMANCE – SUMMARY P&L NZ$'000's year ended 31 March 2018 % of 2017 % of For personal use only revenue revenue Revenue 80,071 69,205 Cost of Sales (45,880) 57.3% (43,207) 62.4% Gross Profit 34,191 42.7% 25,998 37.6% Other Income 2,235 2.8% 2,659 3.8% Selling and distribution expenses (2
Slide 13: Financial Performance – Summary Balance Sheet
FINANCIAL PERFORMANCE – SUMMARY Balance Sheet NZ$'000's year ended 31 March 2018 2017 ASSETS Current Assets Inventories 24,412 22,198 For personal use only Trade and other receivables 16,954 16,051 Cash and cash equivalents 6,770 15,905 Derivative assets 176 - Total current assets 48,312 54,154 Non-
Slide 14: Financial Performance – Summary Cashflow
FINANCIAL PERFORMANCE – SUMMARY Cashflow NZ$'000's year ended 31 March 2018 2017 For personal use only Net cash used in operating activities (10,904) (19,062) Net cash used in investing activities (5,855) (1,598) Net cash generated from financing activities 7,600 9,042 Net increase in cash (9,159) (
Slide 15: Maxigesic – Why is it an important product?
Maxigesic – Why is it an important product? Deaths in USA from opioid overdose For personal use only 8 0 ,0 0 0 T o ta l O v e rd o s e D e a th s O p io id D e a th s 6 0 ,0 0 0 A ID s p e a k (1 9 9 5 ) M o to r V e h ic le D e a th s 4 0 ,0 0 0 2 0 ,0 0 0 0 1 9 9 9 2 0 0 2 2 0 0 5 2 0 0 8 2 0 1 1
Slide 16: Maxigesic – Development Progress Report
Maxigesic – Development Progress Report Dose Form August 17 August 18 For personal use only Oral Tablets EU In registration in 10 EU Finalised registration in 25/28 EU countries [AT, BE, DE, ES , states FR, HR, NL, IE, LX, PT] Filed remaining EU - C Y, EL, LT Oral Tablets US A Filed with FDA S ubmit
Slide 17: Maxigesic – Clinical Trial Progress since IPO
Maxigesic – Clinical Trial Progress since IPO Clinical Trial Type No. of Territories Subjects For personal use only AFT-MX13A Phase 1 PK S tudy (Maxigesic 325 30 Jordan Tablets - fasting) AFT-MX13B Phase 1 PK S tudy (Maxigesic 325 30 Jordan Tablets - fed) AFT-MX-16A Phase 1 PK S tudy (Maxigesic Rapi
Slide 18: Maxigesic Global Update
Eastern Europe and Balkans – MAXIGESIC GLOBAL UPDATE Nordics – launch pending 4Q FY19 launches pending FY19 BE/LX & FR– launches pending Italy – successful launch and 4Q18 sales growing still NL – licensing discussions Germany – licensing UK – launched underway underway Licensing discussions startin
Slide 19: Maxigesic countries launched and launch plan
Maxigesic countries launched and launch plan For personal use only 10A Annual Meeting 19 2 August 2018
Slide 20: Example of Maxigesic Licensee Progress to Date
EXAMPLE OF MAXIGESIC LICENCEE PROGRESS TO DATE – tablet sales per month For personal use only 1,400,000 1,200,000 1,000,000 800,000 600,000 400,000 200,000 - Annual Meeting 20 2 August 2018
Slide 21: International Sales to Grow
International Sales to Grow Net Revenue FY' 19 2.2% 6.0% For personal use only 28.4% 63.4% Net Revenue FY' 23 2.4% Au s tra lia Ne w Ze a la nd Inte rna tio na l S o uth e a s t As ia 42.0% 43.6% 12.0% Annual Meeting 21 2 August 2018
Slide 22: Maxigesic: Australian Growth Strategy
MAXIGESIC: Australian growth strategy • Codeine switch occurred 1st February 2018. For personal use only • Maxigesic attained market leadership in the Paracetamol-Ibuprofen category post switch despite being significantly outspent by multinational competitors • Consumer market research indicates fur
Slide 23: Maxigesic: Going Forwards
MAXIGESIC: GOING FORWARDS Additional out-licensing and distribution agreements for Maxigesic oral dose forms have been secured to increase the number of countries to 125 from 110. For personal use only Some additional countries still to be added – Up to about 12 Advanced discussions underway includi
Slide 24: NasoSURF Nebuliser: Going Forwards
NASOSURF NEBULISER: Going Forwards Product A handheld ultrasonic nasal mesh nebuliser primarily description for the intranasal delivery of medication For personal use only The NasoSURF Nebuliser has desirable features over currently marketed nebulisers, which are not approved for delivery of specifi
Slide 25: Summary of Medium Term Plans
SUMMARY OF MEDIUM TERM PLANS Key aim is to trade profitably during FY19 For personal use only Further build Maxigesic sales post codeine changes and register and launch line extensions Further build revenues of OTC product sales in Australia and New Zealand Expansion of ANZ Opportunities Advancing a
Slide 26: Questions & Answers
For personal use only Questions & Answers
Slide 27: Ordinary Resolutions
For personal use only Ordinary Resolutions
Slide 28: Ordinary Resolution 1
ORDINARY RESOLUTION 1 For personal use only 1. 1. That the directors are authorised to fix the fees and expenses of Deloitte as auditor for the 2019 financial year. Annual Meeting 28 2 August 2018
Slide 29: David Flacks
DAVID FLACKS For personal use only Annual Meeting 29 2 August 2018
Slide 30: Ordinary Resolution 2
ORDINARY RESOLUTION 2 For personal use only 2. That David Flacks be re-elected as a director of AFT. Annual Meeting 30 2 August 2018
Slide 31: Jim Burns
JIM BURNS For personal use only Annual Meeting 31 2 August 2018
Slide 32: Ordinary Resolution 3
ORDINARY RESOLUTION 3 For personal use only 3. That Jim Burns be re-elected as a director of AFT. Annual Meeting 32 2 August 2018
Slide 33: Close of Meeting
For personal use only Close of Meeting – thanks for attending
AFT Pharmaceuticals — Shareholder Meeting (August 2018) on 6ix